Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Free Report) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 54,000 shares, a decline of 43.4% from the September 30th total of 95,400 shares. Based on an average daily volume of 58,900 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the company’s shares are short sold.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on PSTV. Ascendiant Capital Markets lowered their price objective on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a research note on Friday, August 16th.
Check Out Our Latest Stock Report on Plus Therapeutics
Hedge Funds Weigh In On Plus Therapeutics
Plus Therapeutics Stock Performance
PSTV stock remained flat at $1.35 during trading on Friday. 22,169 shares of the company were exchanged, compared to its average volume of 57,138. Plus Therapeutics has a 12 month low of $1.01 and a 12 month high of $2.78. The business’s 50 day moving average price is $1.44 and its 200 day moving average price is $1.71. The stock has a market cap of $7.70 million, a P/E ratio of -0.44 and a beta of 0.67.
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. The firm had revenue of $1.28 million during the quarter. Analysts forecast that Plus Therapeutics will post -2 earnings per share for the current year.
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Featured Stories
- Five stocks we like better than Plus Therapeutics
- What is a Death Cross in Stocks?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Overbought Stocks Explained: Should You Trade Them?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What is a buyback in stocks? A comprehensive guide for investors
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.